Stock 600332 GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Shanghai S.E.

Equities

600332

CNE000001733

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-07-08 pm EDT 		5-day change 1st Jan Change
29.38 CNY +0.69% Intraday chart for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited -0.64% +2.73%
Jun. 27 Guangzhou Baiyunshan Pharmaceutical Secures Drug Registration for Erectile Dysfunction Tablets MT
Jun. 19 Baiyunshan Pharmaceutical's Unit Gets Regulatory Nod to Add Specification for Dopamine Hydrochloride Injection MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The company is in a robust financial situation considering its net cash and margin position.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.2 for the 2024 fiscal year.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED Stock Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
+2.73% 6.26B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+59.97% 840B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.10% 621B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.18% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.61% 319B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.44% 297B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.45% 237B
B+
NOVARTIS AG Stock Novartis AG
+14.85% 221B
B-
ROCHE HOLDING AG Stock Roche Holding AG
+0.94% 220B
A+
AMGEN INC. Stock Amgen Inc.
+9.68% 169B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 874 Stock
  4. 600332 Stock
  5. Ratings Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited